NASDAQ:CRSP

Crispr Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy CRSP

*Your capital is at risk

$52.08

+0.0600 (+0.115%)

At Close: Jun 03, 2026

CRISPR Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -42.85. In total, the insiders bought 1.4M and sold 364.31K CRSP shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-42.85
● Buy	1.4M shares
● Sell	364.31K shares
66% Buy Activity Moderate Positive Correlation
Sell Signal Medium Confidence Jan 22, 2026 Analysis Breakdown: Supported by a negative Insider Power Score of -42.85. Partially supported by a positive historical correlation. Confidence increased due to high data reliability score of 90.

Historical Insider Trades

Date	Type	Person	Role	Amount
May 29, 2026 Buy	Restricted Stock Units A-Award	Prasad Raju Chief Financial Officer	C-Suite Officer	19 500 Value: $1.10M
May 29, 2026 Buy	Restricted Stock Units A-Award	Kasinger James R. General Counsel And Secretary	Officer	17 000 Value: $955.1K
May 29, 2026 Buy	Restricted Stock Units A-Award	Patel Naimish Chief Medical Officer	Officer	22 000 Value: $1.24M
May 29, 2026 Sell	Common Shares S-Sale	Patel Naimish Chief Medical Officer	Officer	3 786 Value: $210.6K
May 28, 2026 Buy	Restricted Stock Units M-Exempt	Patel Naimish Chief Medical Officer	Officer	10 000 Value: $563.8K
May 28, 2026 Buy	Common Shares M-Exempt	Patel Naimish Chief Medical Officer	Officer	10 000 Value: $563.8K
Mar 23, 2026 Sell	Common Shares S-Sale	Prasad Raju Chief Financial Officer	C-Suite Officer	3 708 Value: $173.5K
Mar 23, 2026 Sell	Common Shares S-Sale	Kulkarni Samarth Chief Executive Officer	CEO / President	10 020 Value: $468.7K
Mar 23, 2026 Sell	Common Shares S-Sale	Kasinger James R. General Counsel And Secretary	Officer	3 182 Value: $148.9K
Mar 20, 2026 Buy	Restricted Stock Units A-Award	Patel Naimish Chief Medical Officer	Officer	30 000 Value: $1.39M
Mar 20, 2026 Buy	Restricted Stock Units M-Exempt	Prasad Raju Chief Financial Officer	C-Suite Officer	6 250 Value: $289.0K
Mar 20, 2026 Buy	Common Shares M-Exempt	Prasad Raju Chief Financial Officer	C-Suite Officer	6 250 Value: $289.0K
Mar 20, 2026 Buy	Restricted Stock Units A-Award	Prasad Raju Chief Financial Officer	C-Suite Officer	27 500 Value: $1.27M
Mar 20, 2026 Buy	Stock Option (Right to Buy) A-Award	Prasad Raju Chief Financial Officer	C-Suite Officer	38 499 Value: $1.78M
Mar 20, 2026 Buy	Restricted Stock Units M-Exempt	Kulkarni Samarth Chief Executive Officer	CEO / President	19 687 Value: $910.3K
Mar 20, 2026 Buy	Restricted Stock Units A-Award	Kulkarni Samarth Chief Executive Officer	CEO / President	81 875 Value: $3.79M
Mar 20, 2026 Buy	Stock Option (Right to Buy) A-Award	Kulkarni Samarth Chief Executive Officer	CEO / President	114 249 Value: $5.28M
Mar 20, 2026 Buy	Common Shares M-Exempt	Kasinger James R. General Counsel And Secretary	Officer	6 250 Value: $289.0K
Mar 20, 2026 Buy	Stock Option (Right to Buy) A-Award	Kasinger James R. General Counsel And Secretary	Officer	38 499 Value: $1.78M
Mar 20, 2026 Buy	Restricted Stock Units A-Award	Kasinger James R. General Counsel And Secretary	Officer	25 000 Value: $1.16M
Mar 20, 2026 Buy	Restricted Stock Units M-Exempt	Kasinger James R. General Counsel And Secretary	Officer	6 250 Value: $289.0K
Mar 20, 2026 Buy	Common Shares M-Exempt	Kulkarni Samarth Chief Executive Officer	CEO / President	19 687 Value: $910.3K
Mar 20, 2026 Buy	Stock Option (Right to Buy) A-Award	Patel Naimish Chief Medical Officer	Officer	38 499 Value: $1.78M
Mar 16, 2026 Sell	Common Shares G-Gift	Prasad Raju Chief Financial Officer	C-Suite Officer	750 Value: $0
Mar 16, 2026 Sell	Common Shares S-Sale	Prasad Raju Chief Financial Officer	C-Suite Officer	4 021 Value: $194.1K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT CRISPR THERAPEUTICS AG

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglo...

Read Full Profile Here